Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly and Company : The underlying trend is in force again

share with twitter share with LinkedIn share with facebook
10/16/2020 | 09:10am EDT
long trade
Live
Entry price : 147.11$ | Target : 169.13$ | Stop-loss : 139$ | Potential : 14.97%
Shares in Eli Lilly and Company do not show any sign of a slowdown in the ascending dynamic. Investors could bet on a continuation of the underlying trend.
Investors have an opportunity to buy the stock and target the $ 169.13.
Eli Lilly and Company : Eli Lilly and Company : The underlying trend is in force again
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • Eli Lilly And Company accounts for 4.45 % of our USA Portfolio. A trade is currently open since 06/30/2020 with a purchase price of $ 162.51. Discover the other 19 stocks of the USA portfolio managed by the MarketScreener portfolio management team.

Strengths
  • The share is getting closer to its long-term support in weekly data, at USD 141.46, which offers good timing for buyers.
  • Graphically speaking, the timing seems perfect for purchasing the stock close to the USD 141.52 support.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • The stock is in a well-established, long-term rising trend above the technical support level at 141.46 USD

Weaknesses
  • Based on current prices, the company has particularly high valuation levels.
Ratings chart
Subsector Pharmaceuticals - NEC
1st jan.Capitalization (M$)Investor Rating
ELI LILLY AND COMPANY8.65%129 444
JOHNSON & JOHNSON-1.06%379 969
ROCHE HOLDING AG-0.81%292 399
PFIZER INC.-3.14%210 050
MERCK & CO., INC.-13.50%198 975
NOVARTIS AG-14.48%190 349
NOVO NORDISK A/S16.68%166 008
ABBVIE INC.-4.78%148 793
ASTRAZENECA PLC6.60%138 189
BRISTOL-MYERS SQUIBB COMPAN..-5.33%136 972
AMGEN INC.-4.30%135 125
More Results


share with twitter share with LinkedIn share with facebook

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2020 23 807 M - -
Net income 2020 6 101 M - -
Net Debt 2020 11 592 M - -
P/E ratio 2020 21,7x
Yield 2020 2,09%
Capitalization 129 B 129 B -
EV / Sales 2020 5,92x
EV / Sales 2021 5,32x
Nbr of Employees 33 625
Free-Float 99,8%
Upcoming event on ELI LILLY AND COMPANY
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 166,47 $
Last Close Price 142,80 $
Spread / Highest target 40,1%
Spread / Average Target 16,6%
Spread / Lowest Target -16,0%
EPS Revisions
Managers
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Joshua L. Smiley Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Aarti S. Shah Chief Information & Digital Officer, Senior VP
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President